Therapeutic potential of targeting the Wnt/β‐catenin pathway in the treatment of pancreatic cancer. Issue 5 (28th October 2018)

• Record Type: Journal Article
• Authors: Javadinia, Seyed Alireza; Shahidsales, Soodabeh; Fanipakdel, Azar; Joudi‐Mashhad, Mona; Mehramiz, Mehrane; Talebian, Sahar; Maftouh, Mona; Mardani, Ramin; Hassanian, Seyed Mahdi; Khazaei, Majid; Ferns, Gordon A.; Avan, Amir
• Is Part Of: Journal of cellular biochemistry. Volume 120:Issue 5(2019)
• Page Start: 6833
• Page End: 6840
• Publication Date: 2018-10-28
• Subjects: pancreas -- therapeutic target -- tumors -- Wnt signaling pathway -- Wnt/ β‐catenin; Cytochemistry -- Periodicals; 572
• DOI: 10.1002/jcb.27835
• Languages: English
• ISSNs: 0730-2312

Abstract

Abstract: The Wnt/β‐catenin pathway is an important, dysregulated pathway in several tumor types, including pancreatic ductal adenocarcinoma. Although the activation of this pathway is an important component of normal development, its aberrant activation resulting from activating or inactivating mutations in the CTNNB1 gene locus, or in the negative regulators AXIN and APC involving stabilization of β‐catenin, and activation of target genes leads to a more aggressive phenotype, suggesting its potential value as a therapeutic target in the treatment of pancreatic ductal adenocarcinoma. A number of small molecule and biologic agents have now been developed for targeting this pathway. This review summarizes the current knowledge about the therapeutic potential of targeting the Wnt pathway with particular emphasis on preclinical/clinical studies in the treatment of pancreatic ductal adenocarcinoma.